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ABSTRACT
Purpose: This study examined the gene copy number
change events at chromosome 20 in gastric cancer, and their
possible relationship with recurrence using cDNA micro-
array-based comparative genomic hybridization.
Experimental Design: Thirty pairs of gastric tumor and
normal gastric tissues were used in the cDNA microarray-
based comparative genomic hybridization. The cDNA micro-
arrays containing 17,000 sequence-verified human gene
probes were used in a direct comparison design, where
genomic DNAs from the normal and tumor tissues were
labeled with fluorescent dyes Cy3 and Cy5, respectively, and
cohybridized. Genes with log2 (Cy5/Cy3) z 0.58 in at least
one case were selected as the amplified genes. In order to
search for the association between gene copy number
changes and the recurrence status, patients were grouped
according to their recurrence status. Gene selection between
the two groups was done, and each patient was given a score
based on the sum of the selected genes’ ratios. Logistic
regression analysis was carried out in order to determine if
the score of a group of patients was correlated with a
recurrence.
Results: A group of genes including NCOA6, CYP24A1,
PTPN1, and ZNF217 was amplified in gastric cancer.
Another group of 39 genes, whose sum of copy number
change levels was significantly associated with a poor
prognosis for recurrence, was selected (P < 0.05).
Conclusion: Ninety-six amplified genes at chromosome
20 of gastric cancer are reported. A scoring system based on
gene copy changes at chromosome 20 can provide an
independent patient grouping system that can distinguish
patient recurrence status and survival.
INTRODUCTION
Even with the dramatic decline in the incidence of gastric
cancer in developed countries, it still remains a leading cause
of cancer death worldwide (1). Even with the rapid advance-
ment of molecular biological techniques, there has been slow
progress in the understanding of the molecular mechanism
of gastric carcinogenesis. This is partly due to the multistep
nature of the carcinogenesis and the need to probe the ex-
pression and interaction of a large number of genes and pro-
teins simultaneously. Genome-wide monitoring of both of the
gene expression and gene copy number changes has now be-
come possible due to microarray technology. In gastric cancer
genomic research, microarrays spotted with more than 20,000
human genes are routinely being used to monitor the expression
pattern of those genes in a single experiment. Oligonucleotide
or cDNA microarrays have been used for a comprehensive
survey of the gene expression profiles of the gastric carcinoma
cell lines (2), to identify the gastric adenocarcinoma metastasis-
related genes in the cell lines derived from a primary tumor
and its metastasis counterpart (3, 4), and to select the gene
sets that can distinguish between the normal and tumor gastric
tissues, or the subtypes of gastric cancer based on gene ex-
pression profiling (5–9).
Another important tool for understanding the various
types of tumorigenesis has been comparative genomic hy-
bridization (CGH), which traditionally employed whole chro-
mosomes (10, 11). Even though these chromosome-scale
CGHs have been informative, the low resolution of sometimes
megabases-long inserts has led to the development of matrix-
based CGH using P1, PAC clones, where the insert sizes
range from 75 to 130 kb in length (12). A breakthrough in the
field of CGH was made when Pollack et al. (13, 14) applied
cDNA microarray technology to probe the gene copy changes
in breast cancer.
Many groups have reported genome instabilities related
with gastric cancer. A recent report by Weiss et al. (15)
specifically determined an amplicon boundary at 20q13.2 region
using BAC clone-based microarrays. The amplified region was
shown to be within anf800-kb-long region of 20q13.2. Two of
the well-known oncogene candidates, ZNF217 and CYP24, were
located within this region. However, many of these BAC array-
based CGH studies have a low resolution and few have searched
for an association between gene copy number change and any
clinical information.
In order to delineate the individual genes that undergo copy
number changes in gastric cancer, a cDNA microarray-based
CGH with 30 pairs of normal and tumor gastric tissues using
cDNA microarrays containing 17,000 human genes were done.
This report highlights two separate but related aspects of the
gene copy number change events in chromosome 20 of gastric
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cancer. The first is a list of amplified genes in human
chromosome 20 of gastric cancer compared with normal gastric
tissues. We report that 96 genes including ZNF217, CYP24A,
and PTPN1 show more than a 1.5-fold increase in the Cy5/Cy3
intensity ratio in the tumor tissues tested.
In many cases of microarray experiments, a correlation
between the expression level of selected genes and the clinical
parameters was obtained when the gene expression signature
comprised of ratios or intensities of several genes. A group of
selected genes, when combined, forms a molecular signature that
provides a high correlation with the clinical information, even
though they do not seem to provide meaningful information
individually (16). Therefore, in the second approach, instead of
selecting the genes that pass the 1.5-fold cutoff line, all of the
genes that passed the microarray spot quality filtering and are
located on chromosome 20 were examined using a t test to
determine if any of the genes, whose copy changes are related
with a recurrence, are selected. For this, the patients were
divided into the recurrent and nonrecurrent group, and the genes
that can discriminate between the two groups were searched.
Using the t test, 5 genes (P < 0.01) and 39 genes (P < 0.05),
whose combined score of copy change ratios could distinguish
between the recurrent and nonrecurrent groups in a statistically
significant manner, were selected.
MATERIALS AND METHODS
Tissue Samples and DNA Isolation. All the experiments
using the patient tissues were done after gaining the approval of
the supervisory committee of the Yonsei University College of
Medicine. Only tissue from the patients who underwent surgery
at the Yonsei University College of Medicine (1997-1999), and
were followed up for at least 5 years after surgery, were used.
Tissues with an at least 70% tumor content were saved as the
tumor tissues. Thirty pairs of normal and tumor gastric tissues
used in these experiments (Table 1) were stored in liquid
nitrogen immediately after surgery. The frozen tissues were
ground to a powder, and the genomic DNA was prepared using
the phenol/chloroform/isoamylalcohol method (17).
cDNA Microarray-Based CGH. The cDNA microarrays
containing 17,000 human gene probes (Genomictree, Daejeon,
Republic of Korea) were used for the microarray CGH. Six
micrograms of the DpnII-digested genomic DNA were purified
using a QIAquick PCR purification kit (QIAgen, Du¨sseldorf,
Germany), and was subjected to fluorescent labeling using a
Bioprime labeling kit (Invitrogen, Carlsbad, CA). The reaction
mixtures were incubated at 37jC for 2 hours in the dark and
were quenched by adding 5 AL of 0.5 mol/L EDTA (pH 8.0).
The microarray slide was incubated in 3.5 SSC, 0.1% SDS
with 10 mg/mL bovine serum albumin for 1 hour at 42jC for
blocking. The genomic DNAs from the normal and tumor tissues
were labeled with Cy3-dCTP and Cy5-dCTP, respectively. A pair
of Cy3- and Cy5-labeled DNAs from a patient was mixed with 30
Ag human Cot-1 DNA, 20 Ag poly (dA)-poly (dT) oligonucleo-
tides, and 100 Ag yeast tRNA. A Microcon-30 filter (Amicon,
Bedford, MA) was used to purify and concentrate the hybridiza-
tion mixture, which was then adjusted to the final concentration of
3.5 SSC and 0.3% SDS in 60 AL. Following denaturation at
100jC for 1.5 minutes and preannealing at 37jC for 30 minutes,
the labeled DNA mixture was applied to the cDNA microarray
and incubated at 65jC for 20 to 30 hours. The slide was then
washed for 2 minutes each in 0.5 SSC/0.01% SDS, 0.06 SSC/
0.01% SDS, and 0.05 SSC, consecutively, at room temperature
and spun-dried. The microarray slides were scanned using a
GenePix 4000B scanner (Axon Instruments, Foster City, CA).
Data Preprocessing. The fluorescence signal was calcu-
lated by subtracting the background intensity from the total
intensity of a spot in GenePix Pro 4.1 software. Spots with poor
signals (F532 ¡1.5  B532 < 0 or F635 ¡1.5  B635 < 0)
were removed from further analysis (spot quality filtering). The
discrepancies in the labeling efficiencies were adjusted by a
‘‘within print-tip Lowess normalization’’ (18). Information
regarding the chromosomal locations of the genes were obtained
from SOURCE http://genome-www5.stanford.edu/cgi-bin/
source/sourceSearch).
Statistical Methods I: Selection of Amplified Genes. This
paper classified the ‘‘copy number alteration’’ into two
categories. The first was ‘‘gene amplification’’, meaning the
conversion of an intact copy of a gene into two copies. For this,
the ‘‘noise level’’ of the fluorescence intensity ratio within the
normal tissues was first calculated. When the normal gastric
tissues from the male (XY) and female (XX) genomic DNAwere
cohybridized in the control microarray CGH experiments, the
genes on the autosomes were varied in log2 (Cy5/Cy3) ratios
within F 0.2 ranges. After adding 1 SD to this, it was decided
that the genes on the normal gastric tissues were varied between
the F 0.3 range of the log2 (Cy5/Cy3) ratios. The average male
to female ratio of the genes on the X chromosomes, XX/X,
which could represent a single gene amplification into two
genes, was calculated and a log2 value of 0.58 was obtained.
Table 1 Clinical information of the patients
Category Class Cases Total
Cox regression
P*
Age < 65 y 15 30 0.823
z 65 y 15
Sex Female 3 30 0.831
Male 27








N1-2 20 27 0.003
N3 7
Recurrence Recurrent 13 27 Dependent on
variables
Nonrecurrent 14
5-Gene groupingy Low 13 27 0.000
High 14
39-Gene groupingz Low 8 27 0.017
Middle 7
High 12
*P values from the Cox regression analysis denote the statistical
significance of survival between clinical classes in each category. Classes
in each category are compared with its relation to survival. Age, sex, and
differentiation do not hold statistical significance at P < 0.05 in survival.
yThe group divided by five genes that have different copy number
changes between recurrent group and nonrecurrent group.
zThe group divided by 39 genes that have different copy number
changes between recurrent group and nonrecurrent group.
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Table 2 Amplified genes in chromosome 20 of gastric cancer
No. Genbank accession No. Symbol Cytoband Average ratio Frequency (%) Reference
1 AI015986 RASSF2 20pter-p12.1 0.94 6.7
2 AA450265 PCNA 20pter-p12 0.61 10
3 AA455969 PRNP 20pter-p12 0.9 13.3
4 R55796 PDYN 20pter-p12 0.66 10
5 AI279333 C20orf155 20p13-p12.3 0.74 10
6 H10761 RNF24 20p13-p12.1 0.74 10
7 AA417279 PTPNS1 20p13 0.79 3.3
8 AA448659 CDC25B 20p13 0.76 3.3
9 AA461071 EST 20p13 0.74 10
10 AA866160 SOX12 20p13 0.61 3.3
11 AA974817 ATRN 20p13 0.95 3.3
12 AA974946 SDCBP2 20p13 0.63 3.3
13 AA974960 NSFL1C 20p13 0.77 3.3
14 AI368570 CDS2 20p13 0.65 3.3
15 AI399990 PTPRA 20p13 0.65 6.7
16 AI538521 STK35 20p13 0.66 10
17 AI928276 IDH3B 20p13 0.79 6.7
18 AI017696 MKKS 20p12 1.21 3.3
19 AI620336 PLCB1 20p12 0.98 16.7
20 AI913732 HAO1 20p12 0.6 3.3
21 AA035728 XRN2 20p11.2-p11.1 0.96 3.3
22 AA922705 PYGB 20p11.2-p11.1 0.85 6.7
23 AA424824 DSTN 20p11.23 0.63 6.7
24 AA634360 SEC23B 20p11.23 1.19 3.3
25 AW007634 HARS2 20p11.23 0.59 3.3
26 AA599177 CST3 20p11.21 1.3 3.3
27 AI018501 CRNKL1 20p11.2 0.6 6.7
28 AI348549 C20orf147 20p11.1 1.03 30
29 AA456022 FLRT3 20p11 0.85 10
30 AA910881 EST cen 0.67 3.3
31 AI948413 CBFA2T2 20q11 0.86 3.3
32 AA864524 NCOA6 20q11 0.67 3.3 (22)
33 AA934558 DEFB123 20q11.1 0.9 23.3
34 AA922700 MAPRE1 20q11.1-11.23 1 66.7
35 N39452 EST 20q11.2 0.65 3.3
36 AA699926 SNTA1 20q11.2 1.08 46.7
37 R36886 C20orf104 20q11.22-q11.23 0.7 6.7
38 AA448286 ITCH 20q11.22-q11.23 0.73 16.7
39 AI016688 C20orf52 20q11.23 0.81 40
40 AA996156 SLA2 20q11.23 0.71 3.3
41 AA485922 CPNE1 20q11.23 0.88 10
42 T50121 MAFB 20q11.2-q13.1 0.86 13.3
43 T95014 STK4 20q11.2-q13.2 0.7 13.3
44 AA149097 HCK 20q11-q12 0.81 3.3
45 AI302669 NCOA3 20q12 0.8 20
46 AI279830 PPP1R16B 20q12 0.81 6.7
47 AA683520 SLPI 20q12 0.82 6.7
48 AA283091 KIAA1219 20q12 0.68 3.3
49 AW082097 PI3 20q12-q13 0.71 6.7
50 AI380629 SRC 20q12-q13 0.71 20
51 H18950 SLC13A3 20q12-q13.1 0.89 3.3
52 AI927795 SEMG2 20q12-q13.1 1.8 3.3
53 AI301528 HNF4A 20q12-q13.1 0.95 13.3
54 AA664210 PKIG 20q12-q13.1 0.71 10
55 AA402874 PLTP 20q12-q13.1 0.64 3.3
56 AA683578 ADA 20q12-q13.11 0.83 3.3
57 H82992 PIGT 20q12-q13.12 0.83 3.3
58 AI678253 SEMG1 20q12-q13.2 0.84 13.3
59 W73473 BMP7 20q13 0.61 3.3
60 AI674491 KCNG1 20q13 0.87 36.7
61 AA877213 CYP24A1 20q13 0.72 6.7 (15, 26, 29)
62 H26184 CEBPB 20q13.1 0.83 6.7 (24)
63 AI302973 C20orf111 20q13.11 0.74 6.7
64 AI304790 PTGIS 20q13.11-q13.13 0.64 6.7
65 AA436260 ATP9A 20q13.11-q13.2 0.63 3.3
66 R61289 L3MBTL 20q13.12 0.6 3.3
67 AA918380 ZSWIM1 20q13.12 0.61 3.3
(Continued on next page)
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Therefore, the genes with log2 (Cy5/Cy3) z 0.58 were
determined to be those showing gene amplification. The term
‘‘frequency’’ in the text refers to the percentage of copy number
alteration incidences for each gene from the 30 experiments.
Therefore, after combining the intensity ratios and frequency, the
ratio of log2 (Cy5/Cy3) z 0.58 or V ¡0.58 was observed in at
least 1 of the 30 cases tested (3.3% frequency) for the gene to be
qualified as amplified.
Statistical Methods II: Selection of Genes That Distin-
guish Recurrent and Nonrecurrent Groups. The second
aspect of the gene copy number change events in this paper is the
effect of combined gene copy change ratios. Without consider-
ation of log2 (Cy5/Cy3) having to be > 0.58 or < ¡–0.58, all the
genes that passed quality filtering and that were located at
chromosome 20 were considered. Patients were first divided into
a recurrent and nonrecurrent groups. To evaluate the gene copy
number change and their possible relation to the distinction of
recurrence status of patients, genes that showed differential copy
number changes between the recurrent and nonrecurrent groups
were selected by a t test. The tissue samples without information
for recurrence status were removed from the analysis. From the t
test, 5 genes (P < 0.01), and 39 genes (P < 0.05) containing
these 5 genes, were selected. A modified version of prognostic
scoring system used by Inoue et al. (19) was devised, and each
patient was given a score Si :
Si ¼ 100fkGik
where Si is the score of patient i , and Gik is the log2 (Cy5/Cy3)
of gene k of patient i .
Logistic regression analysis was done to determine if the
score of each patient was correlated with a recurrence. The
patients were classified into two or three groups based on the fact
that Si was likely to reflect the genetic alteration level.
According to the scores of the 5 or 39 genes, 27 patients were
divided into two groups (Table 1; 5-gene grouping of patients) or
three groups (39-gene grouping of patients). In the 5-gene
grouping of the patients, the patients were divided into a high
group with Si z 30 (14 cases) and a low group with Si V 30
(13 cases). In the 39-gene grouping, the patients were divided
into the high group with Si z 292 (12 cases), a middle group with
0 V Si V 292 (7cases), or a low group with Si V 0 (8 cases).
The disease-free survival curves were constructed according
to the Kaplan-Meier method and compared with the G-rho family
of tests including the log-rank and Gehan-Wilcoxon test. Cox
regression analysis was used for multivariate survival analysis
with a backward stepwise selection procedure, and the following
were entered as the categorical covariates: the tumor stage (I, II
versus III, IV), the age at diagnosis (< 65 years, z 65 years),
gender, lymph node metastasis (N1-2 versus N3), and genetic
group based on the selected genes (5-gene grouping, 39-gene
grouping; Table 1). The association between the genetic groups
and the stage groups were analyzed using Fisher’s exact test.
RESULTS
Global View of Gene Copy Number Changes on Chro-
mosome 20 in Gastric Cancers. From the cDNA microarray-
based CGH of the 30 pairs of gastric samples, f13,000 genes
passed the spot quality filtering. Of these, 7,064 genes had
Table 2 Amplified genes in chromosome 20 of gastric cancer (cont’d)
No. Genbank accession No. Symbol Cytoband Average ratio Frequency (%) Reference
68 AA864812 SLC35C2 20q13.12 0.62 6.7
69 AI961669 ARFGEF2 20q13.13 0.7 20
70 AA897418 MOCS3 20q13.13 0.7 3.3
71 AA886333 ADNP 20q13.13 0.9 3.3
72 AA504825 ZNF313 20q13.13 1.06 6.7
73 AA480906 PRKCBP1 20q13.13 0.74 6.7
74 AA004759 DPM1 20q13.13 1.2 3.3
75 R06605 PTPN1 20q13.1-q13.2 0.99 6.7 (22, 23)
76 AA682649 SPATA2 20q13.1-q13.2 0.61 10
77 AI559473 ZNF217 20q13.2 0.86 10 (15, 23, 24, 26, 27)
78 AI302759 C20orf17 20q13.2 0.9 16.7
79 AA069770 KCNB1 20q13.2 0.79 3.3
80 T67004 EDN3 20q13.2-q13.3 0.68 3.3
81 AI393442 SPO11 20q13.2-q13.3 0.79 6.7 (24)
82 AI365196 NFATC2 20q13.2-q13.3 0.8 6.7 (24)
83 AI268751 GNAS 20q13.2-q13.3 1.15 56.7
84 AI700308 PPP1R3D 20q13.3 0.68 3.3
85 AI681381 RPS21 20q13.3 0.94 16.7
86 AA887585 PTK6 20q13.3 0.66 6.7
87 AA700688 ATP5E 20q13.3 0.72 10
88 AI339492 EST 20q13.31 0.7 10
89 AA504128 RAE1 20q13.31 0.75 6.7
90 AA676370 STX16 20q13.32 0.65 10
91 AI986098 MYT1 20q13.33 1.28 6.7
92 AA946732 GTPBP5 20q13.33 0.93 23.3
93 AA910559 C20orf40 20q13.33 1.74 3.3
94 AA863149 PSMA7 20q13.33 0.81 20
95 AA412500 TCEA2 20q13.33 1.24 6.7
96 AA872091 TCFL5 20q13.3-qter 0.63 3.3
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chromosomal location information according to SOURCE (Data
Preprocessing in MATERIALS AND METHODS), and the
mean of log2 (Cy5/Cy3) for 7,064 genes in 30 samples were
plotted according to their chromosomal locations (Fig. 1A): 296
of the 7,064 genes were located on chromosome 20. Of these, 84
(f30%) were located on the p arm, 8 had map locations
spanning the centromere, and the remaining 204 were at the
q arm of chromosome 20. In order to search for the amplified
genes in chromosome 20, 296 genes were screened for the log2
(Cy5/Cy3) ratios of either z 0.58 in at least 1 (3.3%) out of the
30 samples tested. One hundred and twenty-three genes were
selected and their mean log2 (Cy5/Cy3) values (Fig. 1B) and
Fig. 1 Global view of gene
copy number changes on chro-
mosome 20 in 30 cases of
gastric cancer analyzed by
cDNA microarray-based
CGH. A, 7,064 genes with
known chromosomal location
information were plotted for
their mean of log2 (Cy5/Cy3)
and by chromosome location.
Amplified view of gene copy
change pattern for chromo-
some 1 is shown in the box
with log2 (Cy5/Cy3) range (Y-
axis). Of the 7,064 genes
located on chromosome 20,
296 are plotted by their rela-
tive location (X-axis; A), by
the mean of log2 (Cy5/Cy3;
B), or by frequency (C).
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Fig. 2 A two-way hierarchi-
cal clustering of genes whose
copy number changes are cor-
related with recurrence. Five
genes selected at P < 0.01 (A)
or 39 genes selected at P < 0.05
(B) were clustered and shown
as TreeView dendrograms.
Dendrogram of relative gene
copy increase (red) or decrease
(green) following the scale bar
in log scale (bottom right ).
Yellow bars and blue bars
under the dendrograms, nonre-
current and recurrent groups,
respectively. Patient labels are
shown below the yellow and
blue bars.
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incidences (Fig. 1C) were plotted according to the map
locations. Approximately 30% of the copy number-altered genes
(39 of 123 genes) were located on the p arm of chromosome 20,
whereas the other 70% (84 of 123) had map locations at the
q arm.
Amplified Genes at Chromosome 20 in Gastric Cancer.
This study surveyed the gene amplification only (not the
deletions) at human chromosome 20 [log2 (Cy5/Cy3) z 0.58,
3.3%]. Of the 123 unique genes, 96 passed these criteria
(Table 2); and of the 96 amplified genes, 29 genes (30%) were
located at the p arm, 1 at the centromere region, and 66 (70%) at
the q arm of chromosome 20. The higher frequency of the gene
amplification events at the q arm of chromosome 20 compared
with the p arm, does not necessarily guarantee the true
biologically active gene copy change distribution at the q arm
until proven otherwise, but represents the relative proportions of
the copy changes among the genes spotted on the microarray at
this point. ZNF217 and CYP24A, which are well-known
oncogene candidates that have previously been shown to be
within an amplicon boundary in 20q13.2 of gastric cancer (15),
were among the genes selected.
Association Between the Gene Copy Number Changes
at Chromosome 20 and the Clinical Outcome. Because no
correlations could be found between the gene amplification and
the clinical parameters when the criteria of z 1.5-fold of Cy5/
Cy3 and z 3.3% frequency was used, we examined whether or
not the molecular signature of the combined Cy5/Cy3 of
multiple genes, albeit with low ratios, could provide any useful
information. In order to select the discriminatory genes, we
compared the genetic alteration pattern in the recurrent and the
nonrecurrent group comprising 27 out of the 30 patients whose
recurrence status was known (Table 1). Initially, t tests were used
to select a subset of discriminatory genes from all the genes on
chromosome 20. t tests with nominal P values of 0.01 and 0.05
produced 5 and 39 genes, respectively, of which the 5 genes,
PTPNS1, CST7, PRO0628, PCK1, and COL9A3, with P < 0.01
were also in the 39-gene list with P < 0.05. Two-way
hierarchical clustering showed that these 5 and 39 genes, which
were visualized via TreeView dendrogram, were able to classify
most of the 27 cases into either the recurrent group or
nonrecurrent group based on their copy number change patterns
(Fig. 2). The next stage was to identify any correlation between
the selected groups of 5 or 39 genes and the recurrence status of
the patients. In order to classify the patients according to the
genetic alteration levels of the selected genes, each patient was
given a score using a logistic regression analysis (MATERIALS
AND METHODS). The 27 patients were divided into two or
three groups based on the patients’ scores reflecting the genetic
alteration level (Table 1; Fig. 3), and logistic regression analysis
was done to determine if the score-based grouping of the patients
reflects the recurrence versus nonrecurrence status. The results of
logistic regression analysis confirmed that the scores of each
patient for both of the 5 and 39 genes were strongly correlated
with the recurrence of cancer (P < 0.05 in both cases). Using
Fisher’s exact test, it was confirmed that the genetic subgroups
and the gastric cancer stage were not significantly associated
Fig. 3 Grouping of recurrent
and nonrecurrent patients based
on the combination of gene copy
level. According to the Si for
each patient (see the text),
27 cases are divided into two
groups of low and high in a
‘‘5-gene grouping’’ system or
three groups of low, middle,
and high group in a ‘‘39-gene
grouping’’ system as summa-
rized in Table 1. The low groups
in a 5-gene grouping and a 39-
gene grouping system show
scores in the range of 50 to
24 and 304 to 22, respectively.
The scores of the high group
were from 30 to 90 in a 5-gene
grouping system, and from 311
to 1,152 in the 39-gene grouping
system. These scores significant-
ly correlate with the disease-free
survival of each patient (Fig. 4).
In a 5-gene grouping system, the
median survival was 30 months
for 14 patients who belonged to
the high group, and the median
survival was also 30 months for
12 patients who belonged to the
high group in a 39-gene group-
ing system.
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(P = 0.12). Although the use of a traditional staging system for
determining the prognosis of gastric cancer represents a
statistically significant difference for a nonrecurrence, the Cox
regression analysis result and the Kaplan-Meier curves showed
that the patients grouped according to the alteration of the
specific genes were also highly associated with nonrecurrence
(Fig. 4). The group with a higher level of copy number changes
in the recurrence-related genes on chromosome 20 showed a
shorter survival rate (Fig. 4B and C). Although it was shown that
patients with a late stage disease have a shorter survival rate than
those patients with an early stage disease (P < 0.05; Fig. 4A), the
recurrence difference based on the gene copy number changes
were also statistically meaningful (P < 0.05).
DISCUSSION
Human chromosome 20 is of special interest due to the
presence of a susceptibility locus for hereditary diseases, which
include various types of cancers (20). Genomic instabilities at
chromosome 20, particularly at the 20q13 region, are frequently
examined for the presence of specific oncogenes and gene
amplification events in various types of tumors and/or cancer cell
lines. These genes include CYP24, ZNF217 (15), and BTAK
(21) in gastric cancer; CTSZ, NCOA6, and PTPN1 in pancreatic
cancer (22); E2F1, TGIF2, PTPN1 BTAK, and ZNF217 in
ovarian cancer (23); and AIB4, ZNF217, CYP24, and aurora 2
kinase in breast (24, 25) and colorectal cancer (26). Almost all
these gene amplification events have been examined using the
BAC clone-based approaches. In many cases, these BAC clones
are several hundred kilobases in length, and approaches of single
gene probing, one at a time on a small scale, need to be taken in
order to identify the copy-changed genes specifically. These
laborious and time-consuming approaches often result in the
reconfirmation of a previously known specific gene amplifica-
tion event. On the other hand, cDNA microarray-based CGH can
look at the gene copy change events for all the genes printed on
the array in an unbiased manner. The chromosome 20q13.2
region contains differentially amplified genes in primary and
metastatic colorectal cancer, and the amplification has been
associated with metastasis (27). It has been suggested that there
are amplified genes in the 20q13.2 region other than the well-
known genes including ZNF217. Many reports repeatedly
emphasized that chromosome 20 needs to be examined in more
detail because not only are CYP24 and ZNF217 located in this
specific region of 20q but other BAC array-based CGH
experiments have continuously highlighted this region as being
amplified in various types of tumors. The current study of cDNA
microarray-based CGH analysis provides a list of candidate
amplified genes in chromosome 20 (Table 2). Log2 (Cy5/Cy3) z
0.58 was used to specifically select genes that are amplified. This
is a relatively high level of intensity ratio change for a gene to be
qualified as copy number–changed. We specifically used this
line to select amplified genes that can be confirmed by
independent investigators beyond experimental differences.
Several experiments are in the planning stage in order to
confirm the gene copy number changes shown in this report.
First, some of the well-known amplified genes in gastric cancer
including BTAK are located in 20q. Unfortunately, the cDNA
microarrays used in this study did not contain such probes.
Independent confirmation of the result by fluorescence in situ
hybridization or Southern blotting for some of the amplified
genes in this report together with the genes that have been
reported to be amplified but were not spotted in the cDNA
microarrays, notably, BTAK, aurora kinase, and AIB4, will be
highly meaningful. Second, we were looking for the gene
amplification that could contribute to the linear amplification of
mRNA yield by selecting the genes that are more likely to be
amplified in this study. We have done RNA expression profiling
experiments using the same tissue samples and cDNA micro-
arrays. The genes that are highly correlated in the copy change
and RNA expression are strong candidates for novel oncogenes.
The initial analysis suggests that a comparison of the gene copy
change and RNA expression level might require more than just a
fold change–based gene selection in the two databases and
Fig. 4 Survival rate of 27 gastric cancer patients depending on the
status of gene copy changes in chromosome 20. A, Kaplan-Meier
survival curves of gastric cancer patients divided by tumor stages (stages
I and II versus stages III and IV). Patients with an early stage have a
higher disease-free survival rate than those patients with a late stage
disease. B, survival curves of high, middle, and low groups divided by
the genetic alteration levels of 39 genes that had different copy number
changes between the recurrent group and nonrecurrent group. C, survival
curves of high and low groups divided by the genetic alteration levels of
5 genes that had different copy number changes between the recurrent
group and nonrecurrent group.
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direct comparison. Instead, a comparison of Pearson correlation
coefficients between gene copy number change profile and RNA
expression profile, following the idea of correlation analysis
between gene expression profiles and chemosensitivity profiles
(28), would provide meaningful information.
This study showed that the minimum five genes of
PTPNS1, CST7, PRO0628, PCK1, and COL9A3 comprise a
gene copy change signature and that the copy numbers of these
genes was higher in the patient group with a recurrent gastric
cancer. Furthermore, the patient groups with copy increase for
these genes are strongly correlated with a poor survival (Fig. 4).
This is probably the first study where the gene copy number
changes in chromosome 20 show a direct relationship with the
patient recurrence status. Ongoing data analysis for the
remaining 17,000 genes in the 30 cases of the microarray
CGH will yield an almost complete view of the gene copy
number change events that occur in gastric cancer.
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